Download PDF
Dtsch Med Wochenschr 2020; 145(17): 1258-1270
DOI: 10.1055/a-1117-8446
CME-Fortbildung

Diabetes und Herzinsuffizienz

Diabetes and Heart failure
Philipp H. Baldia
,
Nikolaus Marx
,
Katharina A. Schütt
› Further Information
Also available at
   Permissions and Reprints

Der Diabetes mellitus ist eine wichtige Komorbidität bei Patienten mit Herzinsuffizienz. Liegen beide Erkrankungen gemeinsam vor, verschlechtert dies die Prognose der Patienten nachhaltig. Um das Outcome zu verbessern, sind eine suffiziente Diagnostik und eine differenzierte medikamentöse Therapie von entscheidender Bedeutung. Dieser Beitrag gibt einen Überblick über die Epidemiologie, Pathogenese, Diagnostik und therapeutischen Optionen.

Abstract

Diabetes is a very important comorbidity in patients with heart failure. When both diseases are present, mortality is greatly increased. Therefore, it is important to sufficiently diagnose and treat patients with diabetes and heart failure to improve outcome. This article provides an overview on epidemiology, pathogeneses, diagnostic and therapeutic options.

Schlüsselwörter

Diabetes - Herzinsuffizienz - Pathophysiologie - Diagnose - Therapie

Key words

diabetes - heart failure - pathophysiology - diagnosis - therapy


Publication History

Article published online:
24 August 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Ponikowski P, Voors AA, Anker SD. et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129-2200 . doi:10.1093/eurheartj/ehw128
    CrossrefPubMedGoogle Scholar
  • 2 Nichols GA, Gullion CM, Koro CE. et al The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879-1884 . doi:10.2337/diacare.27.8.1879
    CrossrefPubMedGoogle Scholar
  • 3 Bahrami H, Bluemke DA, Kronmal R. et al Novel Metabolic Risk Factors for Incident Heart Failure and Their Relationship With Obesity. The MESA (Multi-Ethnic Study of Atherosclerosis) Study. J Am Coll Cardiol 2008; 51: 1775-1783 . doi:10.1016/j.jacc.2007.12.048
    CrossrefPubMedGoogle Scholar
  • 4 Nichols GA, Koro CE, Gullion CM. et al The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005; 21: 51-57 . doi:10.1002/dmrr.480
    CrossrefPubMedGoogle Scholar
  • 5 Van Melle JP, Bot M, De Jonge P. et al Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: Data from the heart and soul study. Diabetes Care 2010; 33: 2084-2089 . doi: 10.2337/dc10-0286
    CrossrefPubMedGoogle Scholar
  • 6 Cavender MA, Steg PG, Smith SC. et al Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 2015; 132: 923-931 . doi:10.1161/CIRCULATIONAHA.114.014796
    CrossrefPubMedGoogle Scholar
  • 7 Matsue Y, Suzuki M, Nakamura R. et al Prevalence and Prognostic Implications of Pre-Diabetic State in Patients With Heart Failure. Circ J 2011; 75: 2833-2839 . doi:10.1253/circj.CJ-11-0754
    CrossrefPubMedGoogle Scholar
  • 8 Lehrke M, Marx N. Diabetes Mellitus and Heart Failure. Am J Cardiol 2017; 120: S37-S47 . doi:10.1016/j.amjcard.2017.05.014
    CrossrefPubMedGoogle Scholar
  • 9 Kristensen SL, Preiss D, Jhund PS. et al Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure with Reduced Ejection Fraction: Insights from Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Hear Fail 2016; 9: 1-12 . doi:10.1016/j.amjcard.2017.05.014
    PubMedGoogle Scholar
  • 10 Gustafsson I, Brendorp B, Seibaek M. et al Danish Investigatord of A, Mortality on Dofetilde Study G. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004; 43: 771-777 . doi:10.1016/j.jacc.2003.11.024
    CrossrefPubMedGoogle Scholar
  • 11 Solomon SD, McMurray JJV, Anand IS. et al Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019; 381: 1609-1620 . doi:10.1056/NEJMoa1908655
    CrossrefPubMedGoogle Scholar
  • 12 Buse JB, Wexler DJ, Tsapas A. et al 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43: 487-493 . doi:10.2337/dci19-0066
    CrossrefPubMedGoogle Scholar
  • 13 Cosentino F, Grant PJ, Aboyans V. et al 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2019; 41: 255-323 . doi:10.1093/eurheartj/ehz486
    CrossrefPubMedGoogle Scholar
  • 14 Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 2018; 61: 2098-2107 . doi:10.1007/s00125-018-4669-0
    CrossrefPubMedGoogle Scholar
  • 15 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128 . doi:10.1056/NEJMoa1504720
    CrossrefPubMedGoogle Scholar
  • 16 Neal B, Perkovic V, Mahaffey KW. et al Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657 . doi:10.1056/NEJMoa1611925
    CrossrefPubMedGoogle Scholar
  • 17 Wiviott SD, Raz I, Bonaca MP. et al Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380: 347-357 . doi:10.1056/NEJMoa1812389
    CrossrefPubMedGoogle Scholar
  • 18 McMurray JJV, Solomon SD, Inzucchi SE. et al Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008 . doi:10.1056/NEJMoa1911303
    CrossrefPubMedGoogle Scholar
  • 19 Marso SP, Daniels GH, Brown-Frandsen K. et al Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322 . doi:10.1056/NEJMoa1603827
    CrossrefPubMedGoogle Scholar
  • 20 Marso SP, Bain SC, Consoli A. et al Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844 . doi:10.1056/NEJMoa1607141
    CrossrefPubMedGoogle Scholar
  • 21 Hernandez AF, Green JB, Janmohamed S. et al Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392: 1519-1529 . doi:10.1016/s0140-6736(18)32261-x
    CrossrefPubMedGoogle Scholar
  • 22 Gerstein HC, Colhoun HM, Dagenais GR. et al Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130 . doi:10.1016/s0140-6736(19)31149-3
    CrossrefPubMedGoogle Scholar
  • 23 Aguilar D, Chan W, Bozkurt B. et al Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011; 4: 53-58 . doi:10.1161/circheartfailure.110.952556
    CrossrefPubMedGoogle Scholar
  • 24 Ou SM, Shih CJ, Chao PW. et al Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med 2015; 163: 663-672 . doi:10.7326/m15-0308
    CrossrefPubMedGoogle Scholar